Covaxin’s scientific standards are clear: Bharat Biotech official
Bharat Biotech on Saturday stated scientific standards of the indigenously-developed Covaxin are clear, and the corporate has to date revealed 9 analysis research on its security and efficacy.
“Covaxin’s scientific standards+commitment is transparent. Academic journals, peer reviewers, NIV-ICMR-BB researchers-scientists, 9 studies & data published,” Bharat Biotech co-founder and joint managing director Suchitra Ella stated in a tweet.
“Currently, data from both efficacy and safety follow-up of Covaxin’s Phase III trial is being analysed and compiled. Upholding its uncompromising commitment to integrity, the company will make Phase III trials data from the final analysis public soon,” Bharat Biotech stated in a press release.
The full knowledge for Phase I and II trials, and partial knowledge for the Phase III trial has been completely scrutinised by the regulators in India, the corporate stated.
“In a timely approach to peer review, the company has already published as many as nine research studies on the safety and efficacy of Covaxin in five globally reputed peer-reviewed journals in a span of just twelve months,” it added.
Covaxin, a whole-virion inactivated coronavirus vaccine, is the primary and solely product to have revealed any knowledge from human scientific trials in India, Bharat Biotech stated.
“It is the only product to have any data on emerging variants. It is also the first and only COVID-19 vaccine to have efficacy data in Indian populations,” it added.
Bharat Biotech accomplished three preclinical research, which are revealed in a scientific journal by Cell Press. The research on Covaxin’s Phase I and Phase II scientific trials have been revealed in The Lancet Infectious Diseases, Bharat Biotech stated.
The full knowledge from research on Covaxin’s neutralisation of variants are already revealed at bioRxiv, Clinical Infectious Diseases, and Journal of Travel Medicine, it added.